Effects of H1-Antagonist on Cognition

NCT ID: NCT00846950

Last Updated: 2009-02-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The neurotransmitter histamine appears to be involved in human cognitive performance. However, the exact role is very unclear. The role it plays in memory performance is highly disputed, as animal studies show decreased performance when the H1-receptor is blocked in the central nervous system while such findings in humans is scarce. To clarify the role of histamine in human memory and different processes in cognition, the effects of an H1-antagonist (dexchlorpheniramine) on memory, alertness and sensory and motor processes are measured. The study will be conducted according to a within subject cross-over design using healthy volunteers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy volunteers

Group Type EXPERIMENTAL

dexchlorpheniramine, lorazepam

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dexchlorpheniramine, lorazepam

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy as determined by a physician

Exclusion Criteria

* present or history of any neurological of psychiatric disease
* present or history of any substance abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. A. Vermeeren

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Annemiek Vermeeren, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Maastricht University hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Psychology and Neuroscience, Maastricht University

Maastricht, Limburg, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

06-3-075

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

N-acetylcysteine and NMDA Antagonist Interactions
NCT00611897 COMPLETED PHASE1/PHASE2
Safety of GH001 in Healthy Volunteers
NCT04640831 COMPLETED PHASE1